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Youri Lee1, Jong Seok Lee1,2, Yu-Na Lee1, Soojin Park1, Sang-Moo Kang1*
1 Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University,




Respiratory syncytial virus (RSV) is well-known for inducing vaccine-enhanced respiratory
disease after vaccination of young children with formalin-inactivated RSV (FI-RSV) in alum
formulation. Here, we investigated alum adjuvant effects on protection and disease after FI-
RSV immunization with or without alum in comparison with live RSV reinfections. Despite
viral clearance, live RSV reinfections caused weight loss and substantial pulmonary
inflammation probably due to high levels of RSV specific IFN-γ+IL4-, IFN-γ-TNF-α+, IFN-γ+
TNF-α- effector CD4 and CD8 T cells. Alum adjuvant significantly improved protection as
evidenced by effective viral clearance compared to unadjuvanted FI-RSV. However, in con-
trast to unadjuvanted FI-RSV, alum-adjuvanted FI-RSV (FI-RSV-A) induced severe vac-
cine-enhanced RSV disease including weight loss, eosinophilia, and lung histopathology.
Alum adjuvant in the FI-RSV-A was found to be mainly responsible for inducing high levels
of RSV-specific IFN-γ-IL4+, IFN-γ-TNF-α+ CD4+ T cells, and proinflammatory cytokines IL-6
and IL-4 as well as B220+ plasmacytoid and CD4+ dendritic cells, and inhibiting the induc-
tion of IFN-γ+CD8 T cells. This study suggests that alum adjuvant in FI-RSV vaccines
increases immunogenicity and viral clearance but also induces atypical T helper CD4+ T
cells and multiple inflammatory dendritic cell subsets responsible for vaccine-enhanced
severe RSV disease.
Introduction
Respiratory syncytial virus (RSV) is a major human pathogen that causes bronchiolitis in
infants and young children as well as serious respiratory illness in the elderly and immunocom-
promised adults [1, 2]. RSV infection of mice was shown to induce T helper type 1 (Th1)
immune responses including IFN-γ, IL-2, and IgG2a isotype antibodies as well as Th2 type
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immune responses [3, 4]. RSV-specific CD4 T cell responses play a critical role in the clearance
of virus and immunopathology [5]. Based on cytokine production profiles, Th1 cells produce
IFN-γ, IL-2, and TNF-α whereas Th2 cells produce IL-4, IL-13, IL-6 cytokines associated with
inhibiting development of effector CD8 T cell responses [6–13]. Human trials of formalin-
inactivated RSV (FI-RSV) formulated with alum adjuvant in 1960s caused vaccine-enhanced
respiratory disease resulting in approximately 80% hospitalizations of recipients and two
deaths during RSV epidemic winter season [14]. Mice immunized with FI-RSV in alum formu-
lation were shown to have vaccine-enhanced disease and a high ratio of IL-4 to IFN-γmRNA
in lungs after RSV infection, which was diminished by depleting CD4+ T cells or IL-4 and
IL-10 cytokines [15–17].
Alum adjuvant is widely used in human and animal subunit vaccines. Several studies sug-
gested the potency of alum adjuvant by forming antigen depots in the administration sites and
granting the persistence and prolonged release of antigens [18]. Alum preferentially induces
Th2 cytokines, which modulate the differentiation of Th2 cells and B cells that generate
Th2-associated antibodies (IgG1, IgE) and allergic immune responses [19–22]. Also, alum was
shown to raise proinflammtory mediators including IL-1β, CC-chemokine ligand 2 (CCL2;
MCP1), CCL11 (eotaxin), histamine and IL-5 as well as neutrophils, eosinophils, inflammatory
monocytes, myeloid dendritic cells (DCs), and plasmacytoid DCs [23, 24].
DCs connecting innate and adaptive immunity play an important role in protection and
immunopathology. DCs are divided into multiple subsets including conventional CD11b+,
CD103+, and B220+ plasmacytoid dendritic cells based on their phenotypes in the lung as well
as into lymph node-resident CD4+CD8-, CD4-CD8+, CD4-CD8- DCs [25, 26]. Such DC subsets
have been suggested to be programmed to direct the differentiation of CD4 T cells into either
IFN-γ-secreting Th1 cells or IL-4-secreting Th2 cells [27, 28]. CD11b+ DCs are effective in acti-
vating effector CD4 T cells whereas CD103+ DCs prime naïve CD8 T cells [29]. Plasmacytoid
DCs (pDCs) were shown to be important for inducing antiviral immunity through IFN-α pro-
duction and enhancing CD8 T cell responses during RSV infection [30, 31]. Other studies dem-
onstrated that pDCs contribute to severe RSV disease and elevated mortality during lethal
influenza virus infection [32, 33]. Formalin inactivation of RSV has been considered a major
factor responsible for inducing FI-RSV vaccination-enhanced respiratory disease probably due
to poor induction of neutralizing antibodies [34–37]. However, possible effects of alum adju-
vant on FI-RSV vaccine-enhanced RSV disease, effector T cell responses, and mobilization of
DC subtypes have not been well understood yet despite its common use in human vaccines.
In this study, we have determined the roles of alum adjuvant in inducing humoral and cellu-
lar immune components contributing to immunogenicity, protection, and disease after FI-RSV
vaccination and then RSV infection. We found that alum in FI-RSV (FI-RSV-A) significantly
contributed to enhancing RSV-specific IgG1 isotype antibody responses and clearing lung viral
loads. Nonetheless, FI-RSV-A immune mice showed significant body weight loss and vaccine-
enhanced disease compared to unadjuvanted FI-RSV (FI-RSV) immune mice. Alum in FI-RSV
was found to be responsible for inducing eosinophilia, mucus production, and lung histopa-
thology by increasing RSV specific IL-4+ an TNF-α+ Th2 CD4+ T cell responses, and the mobi-
lization of multiple DC subsets including CD11b+, CD103+, pDCs, and CD4+ DCs.
Materials and Methods
Mice and virus
Six to eight week-old female BALB/c or C57BL/6 (B6) wild type mice were purchased from
Charles River Laboratories International (Wilmington, MA) and Jackson Laboratory (Bar Har-
bor, Maine) respectively. All animal studies were conducted according to the guidelines of
Effects of Alum in FI-RSV Vaccine-Mediated Disease
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Georgia State University Institutional Animal Care and Use Committee (IACUC). RSV A2
strain was originally obtained from Dr. Barney Graham and prepared as described previously
[38].
Cells, antibodies, and Reagents
HEp-2 cells were purchased from the American Type Culture Collection (ATCC, Rockville,
MD, USA) and maintained in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO-BRL,
Grand Island, NY) with 10% fetal bovine serum (FBS, GIBCO-BRL), 2 mM glutamine, penicil-
lin and streptomycin (GIBCO-BRL) at 37°C with 5% CO2. Mouse anti-RSV F monoclonal anti-
body (131-2A) were purchased fromMillipore (Billerica, MA, USA). The horseradish
peroxidase (HRP) conjugated goat anti-mouse immunoglobulin G (IgG), IgG1, and IgG2a
were from Southern Biotech (Birmingham, AL, USA). Aluminum hydroxide (Alum) was pur-
chased from Sigma-Aldrich (St. Louis, MO).
Preparation of formalin-inactivated RSV (FI-RSV) in alum adjuvant
RSV and FI-RSV were prepared in HEp2 cells by modification of the previously reported
method [39, 40]. Briefly, clarified RSV by centrifugation and filtering was inactivated with for-
malin (1:4000 vol/vol) for 72 h at 37°C. FI-RSV was adsorbed to aluminum hydroxide (4mg/
ml) for FI-RSV alum adjuvant vaccine formulation.
Immunization, RSV challenge, and sample collection
Female BALB/c mice (5 per groups) were immunized intranasally (i.n.) with 5 μg of FI-RSV
(approximately equivalent to 1x106 PFU) with or without alum (20 μg or 5 μg alum in 100 μl
FI-RSV per mouse), PBS (naïve control) or infected i.n. with live RSV (1x106 PFU) twice using
a prime-boost protocol at a 4-week interval. Blood samples were collected at 3 weeks after
prime and boost immunization. Unimmunized naive, immunized, or RSV re-infected mice
were i.n. challenged with RSV A2 (2x106 PFU per mouse) under isoflurane anesthesia at 12
weeks after boost immunization and body weight changes were monitored. Mice were scrificed
by carbon dioxide inhalation and a cervical dislocation. Individual samples such as lung, medi-
astinal lymph node (MLN), spleen, bone marrow, and bronchoalveolar lavage fluids (BALF)
were collected at 5 days post-challenge (d.p.c.). Results described in this study were derived
from two independent sets of experiments. All animal studies were conducted according to
the guidelines of Georgia State University Institutional Animal Care and Use Committee
(IACUC). Georgia State University IACUC specifically approved this study. The approved
IACUC protocol number is A14025.
ELISA assay for antibody and cytokines responses
Virus and F or G protein-specific antibody isotypes (IgG, IgG1, and IgG2a) were determined
in samples by enzyme-linked immunosorbent assay (ELISA) as previously described [38, 41].
Briefly, purified live or formalin-inactivated RSV (4 μg/ml) and purified recombinant F (BEI,
NIH) or G protein (100 ng/ml, Sino biological, North Wales, PA) were used as a coating anti-
gen. The antibody responses were detected using the secondary antibodies of HRP-conjugated
goat anti-mouse IgG, IgG1, and IgG2a (Southern Biotechnology). Antibody concentrations
were quantified using the standard curve for each IgG isotype antibodies. The levels of interleu-
kin-4 (IL-4) and IL-6 (eBioscience, SanDiego, CA) and chemokine eotaxin (R&D Systems,
Minneapolis, MN) in lung homogenates were measured using ELISA kits according to the
manufacturer’s instructions.
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RSV immuno-plaque assay
Viral titers in individual lung samples and neutralizing antibody titers in immune sera were
determined using an immuno-plaque assay (IPA) as previously described [38] and [41]. Briefly,
equal volumes of diluted heat-inactivted sera were mixed with 200 PFU/well of RSV A2 and
the immune mixtures or RSV only were incubated for 1 h at 37°C, 5% CO2. The serially diluted
lung homogenates as well as the immune mixtures or virus only were added into monolayer
HEp-2 cells and were adsorbed for 1–2 h then overlaid with growth medium containing 0.8%
low gelling temperature agarose prior to incubation for 3 days. After fixation in formalin, the
plaques were detected using the anti-RSV F monoclonal antibody. The viral titer detection
limit is approximately 40 PFU from lung sample of mouse in this assay.
ELISpot assay
Splenocytes, lung, and bone marrow cells were isolated from tissue samples at 5 d.p.c.. RSV F-
specific antibody secreting cells were determined onMulti-screen 96 well plates (Millipore, Biller-
ica, MA) pre-coated with purified recombinant F protein (400ng/ml) by enzyme-linked immu-
nospot (ELISpot) assay as previously described [42]. The spots of anti-F secreting cells were
developed with biotinylated anti-mouse IgG and streptavidin-AP (Southern) and 3,3’-diamino-
benzidine tetrahydrochloride (DAB, Thermo Scientific). The spots of IFN-γ and IL-4 secreting
cells were determined on Multi-screen 96 well plates coated with cytokine specific capture anti-
bodies as described [40–42]. Briefly, lung cells (0.2x106) per well were cultured with peptide F92-
106 (ELQLLMQSTPATNNR, 4 μg/ml), F85-93 (KYKNAVTEL), G183-195 (WAICKRIPNKKPG),
andM282-90 (SYIGSINNI) as previously described [43, 44]. After 36 h stimulation, the spots were
developed with biotinylated mouse IFN-γ or IL-4 antibody, alkaline phosphatase labeled strepta-
vidin (BD Pharmingen) and then counted using an ELISpot reader (BioSys, Miami, FL).
Flow cytometry
BAL fluids were obtained by infusing 1 mL of PBS into the lungs via the trachea using a 25-gauge
catheter (Exelint International Co., Los Angeles, CA) at 5 d.p.c. and 7 days post immunization
(d.p.i) before challenge infection. Lung cells were isolated by homogenization of tissue through
70 μm cell strainers and Percoll gradient (44% and 67%) centrifugation. For detection of intracel-
lular cytokine-secreting cells, lung cells were stimulated with F92-106, F85-93, G183-195, and M282-90
peptide. Intracellular FACS staining was performed using a cytofix/cytoperm kit (BD Biosci-
ences) according to manufacturer’s instructions. Cells were stained with antibodies for intracellu-
lar cytokines and surface markers including IFN-γ, IL-4 (eBioscience), TNF-α (BioLegend),
CD45, CD3, CD4, CD8, Siglec F (BD Biosciences). To determine memory B cells, plasma cells,
and DC phenotypes, mediastenial lymph node (MLN), spleen, and bone marrow cells were iso-
lated frommice at 5 d.p.c. and 7 d.p.i.. Cells were stained with CD19, IgD, F4/80, CD11b, CD11c,
and PNA or GL7 (eBioscience) as well as with CD45R/B220, CD138, and CD103 (BioLegend).
The PNA+ or GL7+ germinal center B cells and CD138+ plasma cells were analyzed from pre-
gated mature B cells (CD19+IgD-B220+/CD4-CD8- and CD19+IgD-B220int/CD4-CD8-) in
spleens andMLN. The DC populations of B220+, CD103+ and CD11b+ in MLN and lungs were
determined from pre-gated CD11c+F4/80- cells. Stained cells were acquired on a FACSCanto
flow cytometer (BD), and analyzed using Flow Jo software (Tree Star Inc., Ashland, OR).
Lung histopathology
The lungs collected at 5 d.p.c. and 7 d.p.i. were fixed with 10% formalin in PBS, embedded in
paraffin blocks. Lung tissue sections were stained with hematoxylin and eosin (H&E) and
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periodic acid-schiff stain (PAS) to assess histologic changes and airway mucin expression
respectively as described [45]. The sections were examined to score the degree of inflammation
in interstitrum or alveolar spaces as described [46, 47]. PAS-positive spots were detected in 25
randomly selected area in the airway epithelium.
Statistical analysis
The data obtained using the mean and the standard error of means (SEM) value from two indepen-
dent experiments and 5 mice per group. The statistical analyzes were performed by either a one-
way ANOVAwith Tukey multiple comparison test or two-way ANOVA in GraphPad Prism ver-
sion 5 (GraphPad software Inc, San Diego, CA). A p value less than 0.05 was considered significant.
Results
Alum significantly enhances RSV specific antibody responses and
neutralizing activity
The underlying mechanisms by which FI-RSV-A immunization induces vaccine-enhanced RSV
disease have not been well understood. RSV F and G proteins are the major targets for neutraliz-
ing antibodies. We investigated the effects of alum adjuvant on the immunogenicity of FI-RSV
after intranasal immunization of mice with alum-adjuvanted FI-RSV (FI-RSV-A) in comparison
with unadjuvanted FI-RSV (FI-RSV) and live RSV reinfections (live RSV). First, we evaluated
RSV F and G-specific antibody responses (Fig 1). Live RSV-reinfected mice showed highest levels
of IgG2a isotype antibodies specific for RSV F and G. Boost IgG1 antibodies in the FI-RSV-A
group were comparable to those in the live RSV group whereas IgG2a isotype antibodies were
lower than those in the live RSV group (Fig 1A and 1B). Prime immunization with FI-RSV did
not induce RSV specific antibodies at detectable levels and boost immunization with FI-RSV
induced RSV F (but not RSV G) specific antibodies at low levels (FI-RSV, Fig 1A and 1B).
FI-RSV-A immune mice showed higher levels of IgG1 and IgG2a isotype antibodies specific for
RSV F in boost sera compared with those of FI-RSV immune mice (Fig 1A and 1B).
We further analyzed the levels of RSV-specific antibody responses in immune sera using
whole live RSV or FI-RSV as an ELISA coating antigen (Table 1). As shown in Table 1, mice
with live RSV reinfections showed significantly higher levels of serum IgG2a antibodies com-
pared with those in FI-RSV-A and FI-RSV immune mice. As expected, FI-RSV-A immune
mice showed higher levels of IgG1 antibodies in boost sera than those of FI-RSV immune mice
(Table 1).
Neutralizing antibody is an important parameter in protective efficacy against RSV infec-
tion. We determined neutralizing activity against RSV in boost immune sera using a plaque
reduction assay (Fig 1C). The neutralizing titers of FI-RSV-A immune sera were approximately
54% and 31% in 320 and 640 fold dilutions respectively. The FI-RSV-A group showed higher
neutralizing activity compared to that of FI-RSV immune mice that showed approximately
14% of plaque reduction with 640-fold diluted sera (p<0.05, Fig 1C). As expected, live RSV
immune sera showed highest neutralizing activity of 90% and 75% in 320 and 640 fold-diluted
sera (Fig 1C). These results suggest that alum adjuvant in FI-RSV vaccines significantly
enhances RSV specific binding and neutralizing antibody responses.
Alum in FI-RSV is an effective adjuvant in clearing lung viral loads but
leads to severe weight loss
Mice were challenged with RSV at 12 weeks after boost immunization and weight changes of
mice were monitored (Fig 2). Mice with live RSV reinfections showed approximately 15% of
Effects of Alum in FI-RSV Vaccine-Mediated Disease
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weight loss at 2 d.p.c., and then recovered faster than RSV primary infected naïve mice (Live
RSV, Fig 2A). FI-RSV-A immune mice exhibited 20 to 25% of severe weight loss at 2 to 3 d.p.c.,
Fig 1. Alum adjuvant in FI-RSV enhances RSV specific antibody responses and neutralizing activity. The levels of isotype IgG antibodies specific for
RSV F and G protein were measured in serum samples at 3 weeks after prime and boost administration (n = 5). (A) RSV F specific IgG1 and IgG2a isotype
antibodies. (B) RSVG specific IgG1 and IgG2a isotype antibodies. (C) RSV neutralizing activity. Naïve: unimmunized mice, live RSV: re-infection of mice
with RSV A2 (1x106 PFU), FI-RSV-A: mice with i.n. immunization with FI-RSV in the alum adjuvant formulation, FI-RSV: mice with i.n. immunization with
FI-RSV without alum. Results are presented as mean ± SEM. Statistical significances were performed by two-way ANOVA in GraphPad Prism; *** p<0.001,
* p<0.05. ND: Not detected.
doi:10.1371/journal.pone.0139916.g001
Table 1. The levels of antibodies to purified live and formalin inactivated RSV in immune sera. The levels of IgG isotype and IgA antibodies specific
for purified live RSV and FI-RSV were measured in serum samples at 3 weeks after prime and boost administration.
RSV-speciﬁc antibodies (ng/mL)
IgG IgG1 IgG2a IgA
Group Prime Boost Prime Boost Prime Boost Boost
PBS 243±00 347±00 56±03 104±01 240±02 272±02 8±00
Live RSV 5,954±21 7,738±33 2,536±26 3,536±22 4,615±17 8,518±13 338±00
FI-RSV alum 2,712±19 5,995±39 1,389±24 3,197±01 551±05 1,819±18 163±01
FI-RSV 1,054±03 4,068±16 257±01 1,974±04 340±02 1,923±05 200±00
Formalin inactivated RSV-speciﬁc antibodies (ng/mL)
IgG IgG1 IgG2a IgA
Group Prime Boost Prime Boost Prime Boost Boost
PBS 184±02 224±08 31±00 50±00 181±03 233±01 18±00
Live RSV 5,731±11 7,269±08 3,130±07 3,512±07 2,301±08 8,225±33 240±11
FI-RSV alum 1,993±02 6,245±28 1,520±22 3,060±17 681±01 3,284±99 86±03
FI-RSV 708±04 2,498±19 162±01 1,381±06 335±03 1,313±02 28±00
doi:10.1371/journal.pone.0139916.t001
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whereas FI-RSV immune mice displayed approximately 17% of weight loss at 3 d.p.c.
(FI-RSV-A versus FI-RSV, Fig 2B).
Mock (PBS) treated naïve mice or FI-RSV immune mice were found to have highest viral
loads in the lungs among the groups. The FI-RSV-A group showed significantly lower levels of
RSV lung titers than those in the FI-RSV group (FI-RSV-A vs. FI-RSV, Fig 2C). FI-RSV
immune mice showed lower RSV titers than naïve mice (PBS versus FI-RSV, Fig 2C). Mice
with prior RSV reinfections almost cleared lung viral loads at 5 d.p.c. (Fig 2C). These results
suggest that alum in FI-RSV is an effective adjuvant in improving pulmonary viral clearance
but causes more severe weight loss compared to FI-RSV.
Alum in FI-RSV contributes to inducing antibody-secreting plasma and
germinal center B cells
To assess antibody-secreting plasma and germinal center (GC) B cell responses, the bone mar-
row, lymph nodes, and spleen cells were collected 7 days post boost immunization for flow
cytometry and ELISpot analysis (Fig 3A–3E). The live RSV reinfection group showed highest
levels of F specific antibody (IgG, IgG1, IgG2a) secreting cell responses in bone marrow, lymph
nodes, and spleen (Fig 3A, 3B and 3C). Alum adjuvant in FI-RSV (FI-RSV-A) resulted in
enhancing IgG isotype particularly IgG1 antibody secreting cell responses in bone marrow,
lymph nodes, and spleens compared to the FI-RSV alone group which induced lowest antibody
secreting cell responses before challenge A (Fig 3A–3C). A similar pattern of total B cells, GC
phenotypic (PNA+B220+CD138-CD19+IgD-) B cells was observed among groups before chal-
lenge (Fig 3D and 3E).
At 12 weeks after boost, we also determined B cell responses day 5 post challenge (Fig 4).
Significantly higher levels of CD138+B220intCD19+IgD- phenotypic plasma cells (p<0.001)
and GC phenotypic B cells (p<0.001) were observed in spleens of live RSV and FI-RSV-A
immune mice compared to those in FI-RSV immune mice (Fig 4A and 4B). Live RSV reinfec-
tion induced highest numbers of RSV F specific antibody secreting cell spots in spleens and
Fig 2. Alum in FI-RSV enhances lung viral clearance but leads to severe weight loss. At 12 weeks post-boost immunization, immune and PBSmock
control mice (n = 5 per group) were i.n. challenged with 2x106 PFU RSV A2. Naïve: unimmunized mice without RSV infection, PBS: PBSmock control mice
with RSV infection, live RSV: live RSV re-infection mice after RSV infection, FI-RSV-A: FI-RSV-A immune mice after RSV challenge, FI-RSV: FI-RSV
immune mice after RSV challenge. (A) Body weight changes in naïve and prior live RSV reinfected mice after RSV challenge. (B) Body weight changes in
naïve, FI-RSV-A, and FI-RSVmice after RSV challenge. (C) RSV titers in lungs. After 5 d.p.c., individual lungs were collected and virus titers were
determined. Results are presented as mean ± SEM (n = 5). Statistical significances were performed by two- or one-way ANOVA and Tukey’s multiple
comparison tests in GraphPad Prism; (A and B) p<0.001, compared with naïve control and immunized or RSV reinfection group; (B) ## p<0.01, ### p<0.001
between with FI-RSV-A and FI-RSV.
doi:10.1371/journal.pone.0139916.g002
Effects of Alum in FI-RSV Vaccine-Mediated Disease
PLOS ONE | DOI:10.1371/journal.pone.0139916 October 15, 2015 7 / 22
bone marrow (Fig 4C and 4D). FI-RSV-A immune mice showed higher levels of RSV F-specific
antibody secreting cell spots in spleen and bone marrow samples than those in FI-RSV immune
mice (Fig 4C and 4D). These results indicate that alum in FI-RSV vaccines contributes to
enhancing RSV F-specific plasma and memory B cell responses.
Alum in FI-RSV contributes to severe pulmonary inflammation, mucus
production, and eosinophilia
Lung tissue sections were stained with H&E at 5 d.p.c. to evaluate pulmonary histopathology.
FI-RSV-A immune mice showed most severe inflammation around the airways, blood vessels,
and interstitial spaces after RSV challenge (Fig 5A and 5C–5E). Live RSV reinfections also
induced substantially high inflammation around the airways, interstitial spaces, and blood ves-
sels, which are similar to those observed in the FI-RSV-A group (Live RSV versus FI-RSV-A,
Fig 5A and 5C–5E). In contrast, FI-RSV immune mice did not induce such high inflammation,
similar to mock control (PBS) mice upon RSV infection (PBS versus FI-RSV, Fig 5A and 5C–
5E). Interestingly, FI-RSV-A and live RSV reinfection group showed significant pulmonary
inflammation at day 7 after boost immunization or live RSV re-infection (Fig A panels A-D in
S1 File).
Fig 3. Antibody-secreting plasma and germinal center B cell responses before challenge. Bone marrow, splenocytes, and MLN (n = 5) were collected
at 7 days post boost immunization (d.p.i.). MLN cells were stained with surface markers to germinal center (GC) B cells (GL7+B220+) by flow cytometry. (A)
RSV-specific IgG (IgG, IgG1, IgG2a) antibody secreting cell responses in bone marrow after 1 day in vitro cultures. (B) RSV specific antibody secreting cell
responses in MLN after 5 day in vitro cultures. (C) RSV specific antibody secreting cell responses in spleens after 5 day in vitro cultures. (D) Total B cells
(CD19+IgD-) at 7 d.p.i.. (E) GC B cells (GL7+B220+) at 7 d.p.i.. Groups are the same as described in the Fig 1. Results are presented as mean ± SEM (n = 5).
Statistical significances were performed by two- or one-way ANOVA and Tukey’s multiple comparison tests in GraphPad Prism; *** p<0.001, ** p<0.01,
* p<0.05.
doi:10.1371/journal.pone.0139916.g003
Effects of Alum in FI-RSV Vaccine-Mediated Disease
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After staining lung sections with periodic acid-schiff (PAS), PAS positive area was analyzed
to determine mucus production (Fig 5B and 5F). In contrast to the FI-RSV-A group that
showed high PAS staining area, the FI-RSV group did not exhibit PAS positive area before or
after challenge indicating no detectable mucus production (Fig 5B and 5F, Fig A panels A-D in
S1 File). Furthermore, highest levels of pulmonary inflammation, mucus production, eosino-
phils, and eotaxin were well correlated with the presence of alum in FI-RSV before (Fig 5G)
or after challenge (Fig 5A, 5B and 5H–5J). Whereas, FI-RSV immune mice did not induce
siglecF+CD11b+ eosinophils (Fig 5G–5I) as determined by flow cytometry analysis before or
after challenge and eotaxin chemokine in lungs (Fig 5J). Interestingly, live RSV reinfections
induced more eosinophils in the airway fluids compared to FI-RSV immunization (live RSV
vs. FI-RSV, Fig 5I). Next, we determined the effects of a lower dose of alum in FI-RSV vaccines
on inducing protection and disease (Fig 6). Interestingly, a low dose alum (FI-RSV-A 5μg)
immune mice displayed less weight loss and suppressed mucus production as well as cleared
lung viral loads (Fig 6A, 6B and 6D). However, pulmonary inflammation scores were only
slightly lower in the low alum-FI-RSV group without a statistical difference (Fig 6C).
Fig 4. RSV F-specific antibody secreting cell responses, and plasma and germinal center B cells after
challenge. Bonemarrow and splenocytes (n = 5) were collected at 5 d.p.c. and splenocytes and MLN cells
were stained with surface markers to assess plasma and germinal center (GC) B cells by flow cytometry.
CD138+B220intPNA- phenotypic plasma cells (A) and PNA+B220+CD138- phenotypic GC B cells (B) in
spleens at 5 d.p.c.. (C and D) RSV F specific antibody secreting cell spots in spleen (5 day) and bone marrow
cells (1 day) after in vitro culture at 5 d.p.c.. Results are presented as mean ± SEM (n = 5). Statistical
significances were performed by two- or one-way ANOVA and Tukey’s multiple comparison tests in
GraphPad Prism; *** p<0.001, ** p<0.01.
doi:10.1371/journal.pone.0139916.g004
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Therefore, these results suggest that inactivation of RSV may not be the major factor in induc-
ing vaccine-enhanced RSV disease and that alum adjuvant in FI-RSV vaccine formulations
appears to be largely responsible for inducing host immune responses of severe lung inflamma-
tion through the mucus production and eosinophilia upon RSV infection.
Alum in FI-RSV induces Th2 cytokines and IL-4 secreting cell responses
in lungs
We determined Th2-biased immune responses by FI-RSV-A before challenge (Fig 7A–7C).
Live RSV immune mice induced higher levels of IFN-γ secreting cells by stimulation with
Fig 5. Alum in FI-RSV enhances inflammation, mucus production, and eosinophilia. (A-F) Lung tissues collected from individual mice (n = 5 per
groups) at 5 d.p.c. were stained with Hematoxylin and Eosin (H&E) and Periodic-Schiff (PAS) to assess peribronchiolar, alveolar pneumonia, and mucus
production. (A) Photomicrographs of H&E. Scale bars indicate 100 μm for 100×. (B) Photomicrographs of PAS. H&E stained tissue sections were scored in
the airways (C), interstitial spaces (D), and blood vessels (E) for quantitative comparison of pulmonary inflammation and histopathology on a scale of 0 to 3
as diagnostic criteria. (F) PAS positive airway mucus production. Airway mucus production was scored as percentages of 5 individual airways in each
mouse. (G) Siglec F+ eosinophils at 7 d.p.i. before challenge. Siglec F+ eosinophils were detected in BAL (bronchoalveolar lavage) cells and lungs from gated
granulocytes (CD11b+CD11c-F4/80+CD45+) by flow cytometry. Siglec F+ eosinophils in lungs (H) and BAL cells (I) at 5 d.p.c.. (J) Eotaxin production was
determined in lung homogenates collected at 5 d.p.c. by ELISA. Results are presented as mean ± SEM. Statistical analysis were analyzed by two- or one-
way ANOVA and Tukey’s multiple comparison test in GraphPad Prism; *** p<0.001, ** p<0.01, * p<0.05. ND: Not detected.
doi:10.1371/journal.pone.0139916.g005
Effects of Alum in FI-RSV Vaccine-Mediated Disease
PLOS ONE | DOI:10.1371/journal.pone.0139916 October 15, 2015 10 / 22
G183-195 or M282-90 peptide (Fig 7B and 7C) in the lung 7 d.p.i. compared to FI-RSV-A immune
mice displaying high levels of IL-4 secreting cell spots upon stimulation with F51-66 or G183-195
(Fig 7A). In contrast to the FI-RSV-A group, the FI-RSV group showed high levels of F peptide
(but not G peptide) specific IFN-γ secreting cell spots and low levels of IL-4 producing cell
spots (Fig 7A and 7B). Interestingly, a low alum (5 μg) dose in FI-RSV resulted in significant
reductions in IL-4 secreting cell spots and an increase in F92-106-specific IFN-γ secreting cell
responses compared to high dose alum FI-RSV immune mice (FI-RSV-A 20 μg) (Fig 6E and
6F).
Fig 6. Effects of a low dose alum adjuvant in FI-RSV on body weight, protection, lung inflammation and effector cells. A low dose of alum (5 μg)
adjuvant effects was compared with FI-RSV-A (with 20 μg alum) after FI-RSV vaccination and RSV challenge of mice (n = 5). (A) Body weight changes. (B)
RSV lung viral titers. (C) Pulmonary inflammation scores. (D) PAS positive mucus production (%). (E) IFN-γ secreting lung cell spots. (F) IL-4 secreting lung
cell spots. Cytokine secreting cell spots were determined after stimulation with CD8 T cell epitope F92-106 peptide or CD4 T cell epitope G183-195. Results are
presented as mean ± SEM. Statistical analysis were analyzed by two-way ANOVA in GraphPad Prism; *** p<0.001, ** p<0.01. ND: Not detected.
doi:10.1371/journal.pone.0139916.g006
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After challenge, we also examined the production of Th1 and Th2 cytokines in the lung
extracts collected at day 5 d.p.c. (Fig 7). The FI-RSV-A group was found to be responsible for
inducing significantly high levels of IL-6 (Fig 7D) and IL-4 (Fig 7E) proinflammatory cytokines
in lungs whereas FI-RSV or live RSV immune mice did not induce IL-4 and IL-6 cytokines in
lung extracts. In addition, highest levels of IL-4 secreting cell spots were detected in the lung
(Fig 7G) from the FI-RSV-A group but not from FI-RSV or live RSV re-infection mice upon in
vitro stimulation with peptide F92-106 or G183-195 (Fig 7G). In contrast, higher numbers of IFN-
γ secreting cells in response to RSV F or G peptide stimulation were observed in the lung from
the live RSV reinfection and FI-RSV groups (live RSV, FI-RSV, Fig 7F) compared to those in
the FI-RSV-A and naïve groups (FI-RSV-A, PBS, Fig 7F). Therefore, our results suggest that
alum in FI-RSV induces predominantly Th2-skewed immune responses through excessive pro-
duction of IL-6 and IL-4 cytokines as well as IL-4 secreting lung cells.
Fig 7. Alum in FI-RSV contributes to inducing Th2 cytokines in the lung.Cytokine levels and cytokine secreting cell responses were determined before
(A-C) or after challenge (D-G). (A-C) Cytokine secreting lung cell spots were determined at day 9 post inoculation (live RSV) or post immunization (FI-RSV-A,
FI-RSV) before challenge. (A) The numbers of IL-4 secreting lung cell spots specific for F51-66 and G183-195 peptides at 7 d.p.i.. (Band C) The numbers of IFN-
γ secreting lung cell spots specific for F85-96, G183-195, and M282-90 peptides at 7 d.p.i.. The spots of IFN-γ and IL-4 secreting cells in lungs were detected by
stimulation with RSV specific peptides for 36 h using ELISpot analysis. (D) IL-6 in lung homogenates collected at 5 d.p.c.. (E-G) Lung cells were cultured
under stimulation with RSV F, G peptide, or inactive RSV (FI-RSV). (E) IL-4 in lungs. The levels of IL-4 were measured in the supernatants harvested after 72
h. (F) IFN-γ secreting lung cell spots. (G) IL-4 secreting lung cell spots. Results are presented as means ± SEM (n = 5). Statistical significances were
analyzed by two-way ANOVA in GraphPad Prism; *** p<0.001, * p<0.05, ND: Not detected.
doi:10.1371/journal.pone.0139916.g007
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Alum in FI-RSV contributes to inducing pulmonary IFN-γ-IL-4+ and IFN-
γ-TNF-α+ memory CD4+ T cells
Using intracellular cytokine staining flow cytometry, we further examined the phenotypes of
pulmonary effector T cells producing IL-4, IFN-γ, and TNF-α cytokines upon in vitro stimula-
tion with RSV F or G peptide (Fig 8, Fig B in S1 File). FI-RSV-A immune mice showed approx-
imately 5 fold higher numbers of IFN-γ-IL-4+ and IFN-γ-TNF-α+ CD4+ T cells from lung cell
cultures with RSV F92-106 peptide stimulation than FI-RSV alone immune mice (p<0.001, Fig
B panels A-B in S1 File). Also, 3–4 fold higher IFN-γ-IL-4+ and IFN-γ-TNF-α+ lung CD4+ T
cells specific for RSV G183-195 peptide were observed in FI-RSV-A immune mice compared to
those in FI-RSV immune mice (p<0.001 between FI-RSV-A and FI-RSV, Fig 8A and 8B). In
contrast, FI-RSV immune mice did not induce IFN-γ-IL-4+ and IFN-γ-TNF-α+ CD4+ T cells in
the lung upon RSV peptide stimulation (Fig 8A and 8B, Fig B panels A-B in S1 File). The live
RSV group showed highest levels of IFN-γ+IL-4-, IFN-γ+TNF-α -, and IFN-γ-TNF-α+ lung
CD4+ T cells (Fig 8A and 8B, Fig B panels A-B in S1 File).
Before challenge infection with RSV, we also examined the effector CD4 and CD8 T cell
responses upon in vitro stimulation of various RSV specific peptides (F51-66, G183-195 as CD4 T
cell epitope, F85-93 andM282-90 as CD8 T cell epitope) to better understand the effector T
cell responses (Fig 8E–8J). Live RSV immune mice induced high levels of IFN-γ secreting CD4 T
cells specific for F51-66 and G183-195 peptides as well as CD8 T cells specific for F85-93 and M282-90
peptides compared to those of other groups. In contrast to the live RSV group, FI-RSV-A
immune mice exhibited significantly higher levels of IL-4 secreting CD4 T cells specific for F51-66
and G183-195 peptides. Also, the FI-RSV-A group showed lower levels of RSV-specific IFN-γ
secreting CD4 T cells with F51-66 and G183-195 peptide stimulation and IFN-γ CD8 T cells with
F85-93 andM282-90 peptide stimulation (Fig 8E–8J). Taken together, these results suggest that
alum adjuvant in the FI-RSV vaccine formulation is mainly contributing to the induction of pul-
monary IL-4+ and TNF-α+ CD4+ T cells post immunization and during RSV infection.
Alum in FI-RSV vaccines inhibits the induction of effector CD8+ T cells
We investigated possible effects of alum adjuvant on inducing lung CD8 T cell responses by
using intracellular cytokine staining flow cytometry analysis. Lung cells from FI-RSV-A
immune mice displayed lower levels of RSV F92-109 or G183-195 peptide-stimulated effector
CD8+ T cells expressing IFN-γ+IL-4- (Fig 8C, Fig B panel C in S1 File), IFN-γ+TNF-α- (Fig
8D), and IFN-γ-IL-4+ (Fig B panel C in S1 File) compared to those in the FI-RSV group. Inter-
estingly, A low dose of alum (5 μg) in FI-RSV resulted in significantly enhancing IFN-γ secret-
ing cell spots upon CD8 T cell epitope RSV F92-108 peptide stimulation and suppressing IL-4
secreting cell spots compared to those in high dose alum FI-RSV immune mice (Fig 6E and
6F). As expected, live RSV reinfections induced substantial levels of lung CD8 T cells produc-
ing IFN-γ+, IL-4+, and TNF-α+ upon RSV peptide stimulation (Fig 8C and 8D). PBS mock
mice infected with RSV also induced relatively high numbers of IFN-γ+ CD8+ T cells in
response to F92-109 or G183-195 peptide stimulation (Fig 8C and 8D, Fig B panels C and D in S1
File). Taken together, these results suggest that alum adjuvant in FI-RSV vaccine formulation
diminishes IFN-γ+ effector lung CD8+ T cell responses after RSV infection.
Alum in FI-RSV vaccines raises recruitment of plasmacytoid and CD4+
dendritic cells
DCs play a critical role in modulating T cell immunity by producing Th1 or Th2 cytokines
upon antigen uptake and presentation [48]. At day 5 post infection, we analyzed different
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subsets of infiltrating DCs into lungs and mediastinal lymph nodes (MLN) using flow cytome-
try analysis (Fig 9). The FI-RSV alum group showed highest cell numbers of B220+ pDCs
(B220+CD11cintF4/80-CD45+) in the lung (FI-RSV-A, Fig 9A). In addition, alum adjuvanted
FI-RSV immune mice displayed significantly higher numbers of pDCs and CD4+ DCs (CD4+-
CD11c+B220-CD103-F4/80-CD45+) in MLN than those in FI-RSV alone immune mice (Fig 9D
and 9E). FI-RSV alone immune mice showed low levels of pDCs and CD4+ DCs, which is simi-
lar to those in PBS control infection or live RSV re-infected mice (Fig 9A, 9D and 9E). CD11b+
Fig 8. Alum in FI-RSV enhances IFN-γ-IL-4+and IFN-γ-TNF-α+ CD4 T cells but inhibits IFN-γ+ CD8+ T cell responses. Lung cells isolated frommice (n = 5
per group) at 5 d.p.c. (A-D: after challenge) or at 7 d.p.i. (E-I: before challenge) were in vitro stimulated with RSV peptides F92-106, F85-90, M282-90, G183-195, or
F51-66 to determine the effector CD8
+ and CD4+ T cell responses by intracellular cytokine staining flow cytometry. (A and B) G183-195-specific CD4
+ T cells
secreting Th1 or Th2 cytokines (IFN-γ+IL-4-, IFN-γ-IL-4+, IFN-γ+TNF-α-, IFN-γ-TNF-α+) at 5 d.p.c.. (C and D) RSV F92-106-specific effector CD8
+ T cells secreting
cytokines (IFN-γ+IL-4-, IFN-γ-IL-4+, IFN-γ+TNF-α-, IFN-γ-TNF-α+) at 5 d.p.c.. (E and F) F51-66-specific CD4
+ T cells secreting IFN-γ or IL-4 cytokines at 7 d.p.i.. (G
and H) G183-195-specific CD4
+ T cells secreting Th1 or Th2 cytokines at 7 d.p.i.. (I and J) RSV F85-90 or M282-90-specific effector CD8
+ T cells secreting IFN-γ+
cytokines at 7 d.p.i.. Results are presented as mean ± SEM (n = 5). Statistical analysis were performed by two-way ANOVA in GraphPad Prism; *** p<0.001,
* p<0.05. ND: Not detected.
doi:10.1371/journal.pone.0139916.g008
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(CD11b+CD11c+F4/80-CD45+) were observed at higher levels in the lung and MLN from
FI-RSV immune mice regardless of alum adjuvant compared to those in live RSV reinfection
or naïve mice (Fig 9B and 9F). High levels of CD103+ (CD103+CD11c+F4/80-CD45+) DCs
were recruited into the lungs from live RSV, FI-RSV-A, FI-RSV immune mice compared to
those in PBS control mice with RSV infection (Fig 9C). Mice with live RSV reinfection showed
lowest recruitment levels of CD103+ DCs into MLN compared to other groups of immune
mice (Fig 9G). Taken together, these results suggest that alum adjuvant in the FI-RSV vaccine
formulation plays a role in recruiting pDCs in lungs and MLN, and CD4+ DCs in MLN.
Discussion
In comparison with live RSV intranasal reinfections, we investigated the possible roles of alum
adjuvant in the protection and lung inflammatory disease after FI-RSV intranasal immuniza-
tion and RSV challenge. FI-RSV alone without alum was found to be weakly immunogenic,
inducing low levels of RSV specific antibodies and neutralizing activity. Alum adjuvant signifi-
cantly increased the levels of IgG1 and IgG2a antibodies specific for RSV F and G proteins. As
expected, live RSV is the most effective platform for inducing RSV specific antibodies, in par-
ticular IgG2a isotype antibodies. Thus, a replicating property of live RSV seems to be an impor-
tant factor for enhancing humoral immune responses in addition to the activation of innate
immune receptors via intact viral antigens and RNAs. Live RSV, FI-RSV-A, and FI-RSV all
showed more antibodies specific for RSV F protein than those for RSV G protein, indicating
Fig 9. Alum in FI-RSV promotes recruitment of plasmacytoid and CD4+ dendritic cells. Lung and MLN cells isolated frommice (n = 5 per group) at 5 d.
p.c. were stained with various surface markers and phenotypes of DC subtypes were determined by flow cytometric analysis. (A) Lung B220+ pDCs. (B) Lung
CD11b+ DCs. (C) Lung CD103+ DCs. (D) B220+ pDCs in MLN. The plasmacytoid DCs (B220+CD11cint) were counted from gated CD103-CD11b-F4/
80-CD45+ cells in lungs and MLN. (E) MLN-resident CD4+ DCs were determined from gated CD11c+CD11b-CD45+F4/80-. (F and G) The population of
CD11b+ and CD103+ DCs were detected from gated CD11c+CD11b-CD45+F4/80- DCs in lungs and MLN. Results are presented as mean ± SEM (n = 5).
Statistical analysis was performed by one-way ANOVA in GraphPad Prism; *** p<0.001. ND: Not detected.
doi:10.1371/journal.pone.0139916.g009
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that F is more immunogenic than G protein. Inclusion of alum adjuvant in FI-RSV vaccines
significantly increased levels of RSV neutralizing activity, plasma cells, memory B cells, and
germinal center B cells, contributing to clearing lung viral loads. As expected, this study pro-
vides further evidence that alum adjuvant was required to enhance immunogenicity and pro-
tective efficacy of FI-RSV. The effective clearance of lung RSV loads by FI-RSV alum
immunization is consistent with the results in previous studies [39, 49, 50].
Despite the fact that live RSV re-infection was highly effective in clearing lung viral loads,
body weight loss was substantial in mice with prior RSV reinfections, which was similar to
naïve mice displaying highest lung viral loads. Consistently, FI-RSV-A immune mice showed
more weight loss than FI-RSV immune mice after RSV challenge infection. There is no good
correlation between RSV lung viral loads and RSV disease in mice since RSV disease of body
weight loss was observed regardless of lung viral loads, implicating a limitation of murine mod-
els. Nonetheless, results in this study provide convincing evidence that alum adjuvant in the
FI-RSV vaccine formulation is contributing to the induction of cellular immune responses
associated with FI-RSV vaccine-enhanced respiratory disease.
Histopathology is an important parameter for assessing pulmonary RSV disease. Addition
of alum adjuvant to FI-RSV was found to exacerbate pulmonary histopathology as evidenced
by highest inflammation scores around the airways, interstitial spaces, and blood vessels. Severe
pulmonary inflammation in FI-RSV alum immune mice showed correlations with high levels
of infiltrating immune cells and granulocytes, particularly eosinophils, mucus and eotaxin
production as well as IL-6 and IL-4 inflammatory cytokines in the lung and BAL fluids of
alum-adjuvanted FI-RSV (FI-RSV-A) immune mice, which were not observed in mice with
inactivated RSV (FI-RSV) alone immune mice. These results in this study are consistent with
previous studies reporting that Th2 cytokines and chemokines were associated with pulmonary
eosinophilia and RSV vaccine-enhanced disease [12, 51, 52]. Live RSV re-infection also
resulted in substantial degrees of lung inflammatory histopathology, which is similar to
FI-RSV alum immunization but more than non-adjuvanted inactivated RSV alone. Thus, sim-
ply inactivating RSV would not be a major factor for inducing RSV disease in mice. This is also
true that mice immunized with recombinant vaccinia virus expressing RSV G displayed severe
lung eosinophilia and weight loss after RSV challenge [53]. Interestingly, co-immunization of
UV-inactivated RSV with poly IC, Toll-like receptor (TLR) 3 agonist, or lipopolysaccharide, a
TLR4 agonist was shown to diminish UV-inactivated RSV vaccine-enhanced lung inflamma-
tion [34]. Further studies are needed for better understanding the adjuvant effects of TLR ago-
nists on improving RSV vaccine safety.
A previous study of antibody-mediated T cell depletion experiments indicated that T cells
play a role in the progress of RSV disease [54]. However, what types of effector T cells contrib-
uting to disease have not been completely defined yet after alum-adjuvanted FI-RSV vaccina-
tion. Interestingly, intracellular staining flow cytometric analysis in this study found that alum
adjuvanted FI-RSV immunization induced polarized CD4 Th2 effector cells upon in vitro stim-
ulation with F92-106, F51-66, F85-93, and G183-195 peptides. In other words, F92-106-stimulated
IFN-γ-IL4+ and IFN-γ-TNF-α+ Th2 CD4 T cells as well as G183-195-specific IFN-γ
-IL-4+ Th2
CD4 T cells were observed at significantly higher levels in the lungs of alum-adjuvanted
FI-RSV immune mice than those in FI-RSV alone immune mice without alum adjuvant. It is
interesting to note that high levels of IFN-γ-IL-4+ and IFN-γ-TNF-α+ CD4 T cells in response
to CD8 T cell epitope F92-106 peptide stimulation were observed in the FI-RSV-A group as
determined by intracellular cytokine staining (Fig A panels A-B in S1 File). It might be possible
to induce CD4 T cells from alum-adjuvanted FI-RSV-A immune mice through bystander stim-
ulation with 15-mer F peptides in vitro. In contrast, the induction of CD8 T cells in response to
CD4 T cell epitope G183-195 peptide stimulation was inhibithed in FI-RSV-A immune mice
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compared to FI-RSV mice without alum (Fig B panels C-D in S1 File). It is still unclear how the
G183-195 peptide known to be a CD4 T cell epitope can stimulate CD8 T cells. Th2 type CD4 T
cells responding to both RSV F and G peptide stimulation might be due to bystand stimulation
through high levels of IL-4 cytokine and contributing to alum-adjuvanted FI-RSV vaccine-
enhanced pulmonary histopathology. Whereas live RSV re-infection induced high levels of
IFN-γ+IL-4- and IFN-γ+TNF-α- Th1 CD4 T cells as well as IFN-γ-TNF-α+ CD4 T cells in
response to RSV F and G peptide stimulation. High levels of Th1 type CD4 T cells are also con-
sidered to be involved in RSV disease as evidenced by weight loss and pulmonary histopathol-
ogy in the live RSV group. FI-RSV alone immune mice showed low levels of cytokine-secreting
CD4+ T cells, which might be contributing to less pulmonary inflammation. Therefore, this
study provides evidence that high levels of IFN-γ-IL-4+ and IFN-γ-TNF-α+ CD4 T cells might
be associated with pulmonary histopathology, which are highly induced by alum adjuvant in
FI-RSV.
Mice with RSV re-infection induced high levels of IFN-γ+IL-4-, IFN-γ-IL-4+, IFN-γ-TNF-
α+, and IFN-γ+TNF-α- CD8 T cells upon in vitro stimulation with RSV F and G peptides in
contrast to mice with alum-adjuvanted FI-RSV that showed very low levels of effector CD8 T
cells. Therefore, RSV re-infection can induce RSV specific effector CD4 and CD8 T cells pro-
ducing both Th1 and Th2 type cytokines whereas alum-adjuvanted FI-RSV prefers to stimulate
IL-4+ or TNF-α+ Th2 CD4 T cells but not effector CD8 T cells. Whereas primary RSV infection
(naïve mice with RSV) or FI-RSV alone immune mice are likely to induce RSV F and G specific
CD8 T cells expressing IFN-γ+ but not IL-4+ CD4 T cells. Experimental evidence in this study
suggests that alum adjuvant in FI-RSV suppresses the induction of RSV specific IFN-γ+ CD8 T
cells. RSV specific effector T cell responses are differentially induced depending on primary
RSV infection of naïve mice (PBS mock control), RSV re-infection, alum-adjuvanted FI-RSV,
or inactivated RSV immunization.
Both FI-RSV with and without alum groups were significantly lower in the levels of IFNγ
producing CD4 and CD8 T cells, in particular F and M2 specific IFN-γ CD8 T cells (Fig 8, Fig
B panels C-D in S1 File). Alum adjuvant in FI-RSV appeared to suppress the induction of IFN-
γ CD8 T cells compared to FI-RSV without alum. Since there was no significant difference in
lung viral loads between the live RSV and FI-RSV plus alum groups, CD8 T cells might not be
required for clearing lung viral loads of RSV. In line with this notion, depletion of CD8 T cells
after primary RSV infection of mice was reported not to affect clearing lung viral loads during
re-infection with RSV [34]. Instead, CD8 T cells are likely to play a role in modulating or sup-
pressing RSV vaccine-enhanced disease. However, high levels of both IFN-γ CD4 and CD8 T
cells might cause pulmonary pathology. These results in this study are consistent with previous
reports that RSV M2 peptide specific IFN-γ CD8 T cells play a significant role in causing CD8
T cell-mediated immunopathology including weight loss in mice upon RSV challenge [55, 56].
In this regard, it is worth noting that RSV re-infection resulted in enhanced levels of both effec-
tor CD4 and CD8 T cells secreting cytokines, which might be responsible for pulmonary
inflammation and weight loss despite effective control of lung viral loads. Therefore, in addi-
tion to RSV neutralizing activity essential for lung viral clearance, induction of regulated and
restricted T cell responses preferentially CD8 T cells as well as preventing excessive CD4 T cell
responses would be important for RSV protection without disease.
It is considered that mobilization of DCs would provide an important immune regulator for
modulating innate microenvironment and adaptive immune T cell responses as well as for pul-
monary histopathology. In particular, different subsets of DCs were suggested to play a critical
role in inducing RSV-specific adaptive immune responses [57]. However, the possible roles of
alum adjuvant in modulating DC subsets as well as in protection and RSV disease are not well
known. FI-RSV alum immune mice displayed approximately 3-fold higher B220+ pDC
Effects of Alum in FI-RSV Vaccine-Mediated Disease
PLOS ONE | DOI:10.1371/journal.pone.0139916 October 15, 2015 17 / 22
populations (B220+CD11cintF4/80-CD45+) in the lung and MLN compared to those in inacti-
vated RSV alone or live RSV immune mice. Therefore, recruitment of high levels of pDCs in
both lungs and MLN is likely to be associated with inflammatory pulmonary RSV disease in
addition to IL-4 and IL-6 proinflammatory cytokines as well as mostly CD4 T cells secreting
IL-4 or TNF-α. Consistent with possible roles of pDCs in RSV disease in FI-RSV alum immune
mice, pDCs were shown to increase mortality during influenza virus infections by inhibiting
CD8 T cell responses [33]. Also, human pDCs and conventional DCs were demonstrated to
induce Th2 responses via polarizing cytokines, costimulatory molecules, and cell surface recep-
tors [58–60]. Detailed analysis of DC subsets in this study also found that alum adjuvant
induced high levels of CD4+ DCs in MLN from FI-RSV alum immune mice. In support of pos-
sible roles of CD4+ DCs in inducing IL-4 cytokine and IL-4+ CD4 T cells in FI-RSV alum
immune mice, CD4+ DCs were reported to enhance Th2 differentiation by inhibiting IL-12
and IFN-γ production [28, 61]. To obtain an insight into differential host responses by alum
adjuvant in FI-RSV, bone marrow derived DCs and macrophages were incubated with live
RSV, FI-RSV plus alum, and inactivated RSV (FI-RSV) alone. The IL-6 and TNF-α cytokines
were detected in culture supernatants at significantly higher levels in stimulation with live RSV
or alum-adjuvanted FI-RSV compared to those with FI-RSV alone (Fig C panels A-B in S1
File). Thus, alum adjuvant in the FI-RSV formulation was found to significantly enhance the
activation of dendritic cells to secrete IL-6 and TNF-α inflammatory cytokines in vitro (Fig C
panels A-B in S1 File). IL-6 is known to inhibit the induction of Th1 immune responses [62].
Thus, the possible modulation of alum adjuvant in activating DCs and macrophage cells might
be supportive of high levels of TNF-α+ CD4 T cells and Th2 (IL-4, IL-6) cytokines in alum-
adjuvanted FI-RSV immune mice.
In summary, live RSV re-infection, alum-adjuvanted FI-RSV, and FI-RSV without alum sig-
nificantly influence the induction of Th1 and Th2 cytokines by differential CD4 and CD8 T
cell responses as well as the mobilization of multiple DC subsets and eosinophils. Both innate
and adaptive host immune components play significant roles in RSV protection and disease in
mice. In particular, alum adjuvant in FI-RSV vaccine formulations has considerable impacts
on increasing immunogenicity and virus clearance as well as Th2 type CD4 T cells, proinflam-
matory cytokines, eosinophilia, mucus production, B220+ pDCs, and CD4+ DCs, and inhibi-
tion of effector CD8 T cells. Results in this study suggest that induction of a balanced immune
response with appropriate CD4 and CD8 T cells, and appropriately regulated innate pulmo-
nary DC subsets in addition to RSV neutralizing activity would be required for a safe and effec-
tive RSV vaccine. Further studies are required to delineate possible roles of respiratory DC
subsets in the RSV protection and pulmonary histopathology with different RSV vaccine
platforms.
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